Top Midday Decliners

MT Newswires Live

Yesterday

Youxin Technology (YAAS) closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.

The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.

Summit Therapeutics (SMMT) said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed "consistent, clinically meaningful improvement" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.

A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.

This "discordant" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.

The shares slumped 26% as volume topped 12.6 million versus the daily average of 3.33 million.

Price: 0.08, Change: -0.03, Percent Change: -26.73

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566639559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566639559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566639559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 02:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566639559","market":"sh","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> Youxin Technology (YAAS) closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.</p><p>The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.</p><p><a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed \"consistent, clinically meaningful improvement\" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.</p><p>A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.</p><p>This \"discordant\" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.</p><p>The shares slumped 26% as volume topped 12.6 million versus the daily average of 3.33 million.</p><p>Price: 0.08, Change: -0.03, Percent Change: -26.73</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-09 02:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Youxin Technology (YAAS) closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.</p><p>The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.</p><p><a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed \"consistent, clinically meaningful improvement\" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.</p><p>A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.</p><p>This \"discordant\" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.</p><p>The shares slumped 26% as volume topped 12.6 million versus the daily average of 3.33 million.</p><p>Price: 0.08, Change: -0.03, Percent Change: -26.73</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566639559","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566639559","pubTimestamp":1757355690,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Youxin Technology  closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.Summit Therapeutics  said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed \"consistent, clinically meaningful improvement\" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.This \"discordant\" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.The shares slumped 26% ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","BK4134":"信息科技咨询与其它服务","SMMT":"Summit Therapeutics PLC","YAAS":"有信云"},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":0.9,"YAAS":0.9},"content_text":"Youxin Technology (YAAS) closed a public offering for gross proceeds of $6 million. The underwriter partially exercised its overallotment option, buying 6.43 million warrants, according to a statement.The stock fell 27% as intraday volume topped 38.5 million shares, compared with the daily average of almost 3.83 million.Summit Therapeutics (SMMT) said Sunday that data from a Phase 3 trial of its investigational antibody ivonescimab, combined with chemotherapy, showed \"consistent, clinically meaningful improvement\" in progression-free survival for patients with certain types of metastatic non-squamous non-small cell lung cancer.A report from medical news outlet Stat News said the company update showed that patients treated with the drug candidate in North America and Europe experienced faster disease progression than those treated in China.This \"discordant\" result may complicate the company's plans to secure approval of the drug candidate in the US and Europe, Stat News said.The shares slumped 26% as volume topped 12.6 million versus the daily average of 3.33 million.Price: 0.08, Change: -0.03, Percent Change: -26.73","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}